Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -7 of 7
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
1/4/2007
 
First Published:
3/1/1995
1.
Phase III Randomized Study of Total Androgen Blockade With or Without Pelvic Irradiation in Patients With Locally Advanced Adenocarcinoma of the Prostate
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
Under 80
NCI
CAN-NCIC-PR3
CALGB-9593, ECOG-JPR03, MRC-PR07, SWOG-JPR3, EU-99013, NCI-T94-0110O, ISRCTN24991896, T94-0110, NCT00002633, PR3
Last Modified:
2/23/2007
 
First Published:
1/1/1999
2.
Phase III Randomized Study of Intermittent Versus Continuous Androgen Suppression in Patients With Prostate-Specific Antigen Progression in the Clinical Absence of Distant Metastases After Prior Radiotherapy for Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
16 and over
NCI
CAN-NCIC-PR7
SWOG-JPR7, ICR-CTSU-JPR7, JPR7, NCT00003653, PR7
Last Modified:
12/1/1997
3.
Phase III Randomized Comparison of DES or Orchiectomy vs Buserelin vs DES/MTX or Orchiectomy/MTX in Newly Diagnosed Clinical Stage D2 Carcinoma of the Prostate with No Prior Chemotherapy or Hormonal Therapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
no age specified
NPCTG-1700
Last Modified:
5/11/2007
4.
Phase III Randomized Comparison of TMX plus the LHRH Agonist Buserelin vs Buserelin Alone vs TMX Alone in Premenopausal Patients with Metastatic or Locally Advanced Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
premenopausal women
EORTC-10881
Last Modified:
9/1/1988
5.
Phase III Randomized Comparison of Orchiectomy vs Buserelin vs Buserelin/Cyproterone Acetate in Patients with Stage D Prostatic Carcinoma Previously Untreated with Chemotherapy or Endocrine Therapy (Summary Last Modified 09/88)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
50 to 80
EORTC-30843
Last Modified:
1/24/2008
6.
Phase III Comparison of Early vs Delayed Endocrine Manipulation (Orchiectomy or LHRH Agonist Therapy) in Previously Untreated Patients with Nonmetastatic Asymptomatic Carcinoma of the Prostate
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
80 and under
EORTC-30891
Last Modified:
9/13/2005
 
First Published:
1/26/2003
7.
Phase I Study of Neoadjuvant Hormonal Therapy and OGX-011 (Clusterin Antisense Oligonucleotide) Before Radical Prostatectomy in Patients With Adenocarcinoma of the Prostate
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
Over 18
Other, Pharmaceutical / Industry
CAN-NCIC-IND153
ONCOGENEX-OGX-01-01, NCT00054106, IND153
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute